Skip Navigation Links

Bookmark and Share
Anji Pharma Launches Phase 3 Trial for ANJ900 to Treat Type 2 Diabetes Patients with Kidney Disease
Gut-targeted metformin is expected to lower blood glucose but limit systemic drug levels, opening treatment options for T2D patients with renal insufficiency CAMBRIDGE, Mass. & SHANGHAI--(BUSINESS WIRE)--#T2D--Anji Pharma (“Anji”) has initiated a pivo...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.